Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

Serum biomarkers provide valuable information about the diagnosis and prognosis of a
wide variety of malignant tumors. Despite the identification of several useful serum …

BACKGROUND: Therapeutic possibilities for non-small cell lung cancer (NSCLC) have
considerably increased during recent decades. OBJECTIVE: To summarize the prognostic …

The aim of the study was to assess the clinical prognostic value of serum cytokeratin 19
fragment (CYFRA 21‐1) and carcinoembryonic antigen (CEA) for non‐small‐cell lung …

Background There is increasing recognition that heart failure (HF) and cancer are conditions
with a number of shared characteristics. Objectives To explore the association between …

Background Serum CYFRA 21–1 is one of the most important serum markers in the
diagnosis of non-small cell lung cancer (NSCLC), especially squamous-cell carcinoma …

The role of serum CYFRA 21-1 level in patients with non-small cell lung cancer (NSCLC)
remains to be defined. To re-evaluate the impact of serum CYFRA 21-1 in NSCLC survival …

Background: Tumor biomarkers are used for predicting therapy effect and prognosis of
patients with non-small cell lung cancer (NSCLC). We focused on their potential role in …

AIM To evaluate the value of Cytokeratin 19 fragment for its survival prognostic indicator and
predictive correlation with clinicopathological features in Non-small Cell Lung Cancer …

Objective: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can
effectively control non-small cell lung cancer (NSCLC). Therefore, EGFR mutations should …